Evan Seigerman

Stories

Bristol Myers lung drug succeeds at low dose, misses at high dose

Called the data 'a derisked regulatory submission path'

Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a Phase 3 trial, but only at the lower of two tested doses. The 60 milligram dose slowed lung function decline in patients with idiopathic pulmonary fibrosis, while the 120 milligram dose fell short of statistical significance.

Updated Oct 29

Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal

New Capabilities

As of September 2026: Monitoring Acadia's phase 3 plans

Acadia Pharmaceuticals said its experimental Alzheimer's psychosis treatment missed the primary goal of a phase 2 trial. The company is advancing remlifanserin to phase 3 anyway, betting a refined study design can turn a near-miss into a win.

Updated Sep 24